Asia Pacific preventive vaccines market will grow by 13.32% annually with a total addressable market cap of $114.84 billion over 2021-2026 owing to the increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 58 tables and 51 figures, this 138-page report ?Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity? is based on a holistic research of the entire Asia Pacific preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
? Market Structure
? Growth Drivers
? Restraints and Challenges
? Emerging Product Trends & Market Opportunities
? Porter?s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Live/Attenuated Vaccines
? Inactivated Vaccines
? Subunit Vaccines
? Toxoid Vaccines
? Conjugate Vaccines
? Recombinant Vector Vaccines
? Other Vaccines
Based on Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Vaccines for Pneumococcal Disease
? Vaccines for Poliovirus
? Vaccines for Hepatitis
? Vaccines for Influenza
? Vaccines for Measles, Mumps, and Rubella (MMR)
? Vaccines for Varicella
? Vaccines for Human Papilloma Virus
? Vaccines for COVID-19
? Vaccines for Other Diseases
Based on Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Intramuscular Route
? Subcutaneous Route
? Oral Route
? Intravenous Injection
? Other Administration Routes
Based on Patient, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
? Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
? Japan
? China
? South Korea
? Australia
? India
? Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific preventive vaccines market are assayed quantitatively and qualitatively through GMD?s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
APAC
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter?s Fiver Forces Analysis 35
3 Segmentation of Asia Pacific Market by Vaccine Type 39
3.1 Market Overview by Vaccine Type 39
3.2 Live/Attenuated Vaccines 41
3.3 Inactivated Vaccines 42
3.4 Subunit Vaccines 43
3.5 Toxoid Vaccines 44
3.6 Conjugate Vaccines 45
3.7 Recombinant Vector Vaccines 46
3.8 Other Vaccines 47
4 Segmentation of Asia Pacific Market by Disease 48
4.1 Market Overview by Disease 48
4.2 Vaccines for Pneumococcal Disease 50
4.3 Vaccines for Poliovirus 51
4.4 Vaccines for Hepatitis 52
4.5 Vaccines for Influenza 53
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54
4.7 Vaccines for Varicella 55
4.8 Vaccines for Human Papilloma Virus 56
4.9 Vaccines for COVID-19 57
4.10 Vaccines for Other Diseases 60
5 Segmentation of Asia Pacific Market by Administration 61
5.1 Market Overview by Administration 61
5.2 Intramuscular Route 63
5.3 Subcutaneous Route 64
5.4 Oral Route 65
5.5 Intravenous Injection 66
5.6 Other Administration Routes 67
6 Segmentation of Asia Pacific Market by Patient 68
6.1 Market Overview by Patient 68
6.2 Pediatric Vaccines 70
6.3 Adult Vaccines 72
7 Asia-Pacific Market 2020-2026 by Country 74
7.1 Overview of Asia-Pacific Market 74
7.2 China 77
7.3 Japan 80
7.4 India 84
7.5 Australia 87
7.6 South Korea 90
7.7 Rest of APAC Region 93
8 Competitive Landscape 95
8.1 Overview of Key Vendors 95
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
AstraZeneca plc 99
Bavarian Nordic A/S 102
China National Biotec Group Company Ltd. 105
CSL Ltd. 107
Daiichi Sankyo Co. Ltd 109
Emergent BioSolutions Inc. 111
GlaxoSmithKline plc 113
Johnson & Johnson 117
Merck & Co. 119
Moderna Inc. 121
Novavax, Inc. 122
Pfizer Inc. 124
Sanofi SA 128
Takeda Pharmaceutical Co. Ltd. 130
9 Investing in Asia Pacific Market: Risk Assessment and Management 132
9.1 Risk Evaluation of Asia Pacific Market 132
9.2 Critical Success Factors (CSFs) 135
Related Reports and Products 138
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026 16
Figure 4. Asia Pacific Preventive Vaccines Market, 2016-2026, $ mn 19
Figure 5. Development Stages of Preventive Vaccines 20
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Preventive Vaccines Market 25
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Preventive Vaccines Market 28
Figure 9. Investment Opportunity Analysis 32
Figure 10. Porter?s Fiver Forces Analysis of Asia Pacific Preventive Vaccines Market 35
Figure 11. Breakdown of Asia Pacific Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue 40
Figure 12. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 40
Figure 13. Asia Pacific Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 41
Figure 14. Asia Pacific Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 42
Figure 15. Asia Pacific Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 43
Figure 16. Asia Pacific Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 44
Figure 17. Asia Pacific Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 45
Figure 18. Asia Pacific Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 46
Figure 19. Asia Pacific Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 47
Figure 20. Breakdown of Asia Pacific Preventive Vaccines Market by Disease, 2020-2026, % of Revenue 49
Figure 21. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 49
Figure 22. Asia Pacific Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 50
Figure 23. Asia Pacific Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 51
Figure 24. Asia Pacific Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 52
Figure 25. Asia Pacific Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 53
Figure 26. Asia Pacific Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 54
Figure 27. Asia Pacific Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 55
Figure 28. Asia Pacific Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 56
Figure 29. Asia Pacific Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 57
Figure 30. Asia Pacific Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60
Figure 31. Breakdown of Asia Pacific Preventive Vaccines Market by Administration, 2020-2026, % of Revenue 62
Figure 32. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 62
Figure 33. Asia Pacific Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 63
Figure 34. Asia Pacific Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 64
Figure 35. Asia Pacific Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 65
Figure 36. Asia Pacific Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 66
Figure 37. Asia Pacific Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 67
Figure 38. Breakdown of Asia Pacific Preventive Vaccines Market by Patient, 2020-2026, % of Revenue 68
Figure 39. Contribution to Asia Pacific 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 69
Figure 40. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 70
Figure 41. Asia Pacific Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 72
Figure 42. Breakdown of APAC Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 75
Figure 43. Contribution to APAC 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76
Figure 44. Preventive Vaccines Market in China, 2016-2026, $ mn 77
Figure 45. Preventive Vaccines Market in Japan, 2016-2026, $ mn 81
Figure 46. Preventive Vaccines Market in India, 2016-2026, $ mn 84
Figure 47. Preventive Vaccines Market in Australia, 2016-2026, $ mn 87
Figure 48. Preventive Vaccines Market in South Korea, 2016-2026, $ mn 90
Figure 49. Preventive Vaccines Market in Rest of APAC, 2016-2026, $ mn 93
Figure 50. Growth Stage of Asia Pacific Preventive Vaccines Industry over the Forecast Period 95
Figure 51. Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars) 100